Bioprosthetic Aortic Valve Degeneration After TAVR and SAVR
Author Information
Author(s): Bismee Nadera N., Javadi Niloofar, Khedr Ahmed, Omar Fatma, Awad Kamal, Abbas Mohammed Tiseer, Scalia Isabel G., Pereyra Milagros, Bcharah George, Farina Juan M., Ayoub Chadi, Sell-Dottin Kristen A., Arsanjani Reza
Primary Institution: Mayo Clinic, Phoenix, AZ, USA
Hypothesis
The review aims to provide a comprehensive overview of the incidence, diagnosis, predictors, and management of bioprosthetic aortic valve degeneration (BAVD).
Conclusion
The study highlights the increasing incidence of BAVD and emphasizes the need for improved imaging techniques and management strategies.
Supporting Evidence
- The incidence of structural valve degeneration (SVD) in bioprosthetic aortic valves increases significantly after 7 to 8 years post-implantation.
- Redo surgical aortic valve replacement has traditionally been the gold standard for managing BAVD but is increasingly being substituted by TAVR.
- Emerging imaging techniques show promise in diagnosing early valve dysfunction.
- Risk factors for BAVD include patient demographics, comorbidities, and procedural variables.
Takeaway
This study talks about how heart valves made from animal tissue can wear out over time, especially in younger patients, and suggests better ways to spot and treat these problems.
Methodology
The review is based on a thorough analysis of existing literature regarding BAVD.
Potential Biases
Potential biases may arise from the selection of studies included in the review.
Limitations
The review may not cover all recent studies or emerging techniques in the management of BAVD.
Participant Demographics
The review discusses various demographics including age, sex, and comorbidities affecting BAVD.
Statistical Information
P-Value
p<0.0001
Confidence Interval
95% CI 0.89−0.94
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website